CYTK
Price
$63.51
Change
-$2.54 (-3.85%)
Updated
Dec 2 closing price
Capitalization
8.08B
91 days until earnings call
Intraday BUY SELL Signals
IMVT
Price
$22.51
Change
+$0.49 (+2.23%)
Updated
Dec 3, 10:30 AM (EDT)
Capitalization
3.99B
77 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CYTK vs IMVT

Header iconCYTK vs IMVT Comparison
Open Charts CYTK vs IMVTBanner chart's image
Cytokinetics
Price$63.51
Change-$2.54 (-3.85%)
Volume$2.15M
Capitalization8.08B
Immunovant
Price$22.51
Change+$0.49 (+2.23%)
Volume$9.78K
Capitalization3.99B
CYTK vs IMVT Comparison Chart in %
CYTK
Daily Signal:
Gain/Loss:
IMVT
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CYTK vs. IMVT commentary
Dec 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CYTK is a StrongBuy and IMVT is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 03, 2025
Stock price -- (CYTK: $63.51 vs. IMVT: $22.02)
Brand notoriety: CYTK and IMVT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CYTK: 114% vs. IMVT: 90%
Market capitalization -- CYTK: $8.08B vs. IMVT: $3.99B
CYTK [@Biotechnology] is valued at $8.08B. IMVT’s [@Biotechnology] market capitalization is $3.99B. The market cap for tickers in the [@Biotechnology] industry ranges from $107.98B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CYTK’s FA Score shows that 1 FA rating(s) are green whileIMVT’s FA Score has 0 green FA rating(s).

  • CYTK’s FA Score: 1 green, 4 red.
  • IMVT’s FA Score: 0 green, 5 red.
According to our system of comparison, CYTK is a better buy in the long-term than IMVT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTK’s TA Score shows that 2 TA indicator(s) are bullish while IMVT’s TA Score has 3 bullish TA indicator(s).

  • CYTK’s TA Score: 2 bullish, 6 bearish.
  • IMVT’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, IMVT is a better buy in the short-term than CYTK.

Price Growth

CYTK (@Biotechnology) experienced а -5.98% price change this week, while IMVT (@Biotechnology) price change was -8.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.91%. For the same industry, the average monthly price growth was -4.84%, and the average quarterly price growth was +52.68%.

Reported Earning Dates

CYTK is expected to report earnings on Mar 04, 2026.

IMVT is expected to report earnings on Feb 18, 2026.

Industries' Descriptions

@Biotechnology (-1.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CYTK($8.08B) has a higher market cap than IMVT($3.99B). CYTK YTD gains are higher at: 35.013 vs. IMVT (-11.102). IMVT has higher annual earnings (EBITDA): -470.69M vs. CYTK (-504.83M). CYTK has more cash in the bank: 858M vs. IMVT (599M). IMVT has less debt than CYTK: IMVT (98K) vs CYTK (858M). CYTK has higher revenues than IMVT: CYTK (85.7M) vs IMVT (0).
CYTKIMVTCYTK / IMVT
Capitalization8.08B3.99B203%
EBITDA-504.83M-470.69M107%
Gain YTD35.013-11.102-315%
P/E RatioN/AN/A-
Revenue85.7M0-
Total Cash858M599M143%
Total Debt858M98K875,510%
FUNDAMENTALS RATINGS
CYTK vs IMVT: Fundamental Ratings
CYTK
IMVT
OUTLOOK RATING
1..100
7660
VALUATION
overvalued / fair valued / undervalued
1..100
100
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
10096
PRICE GROWTH RATING
1..100
3843
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IMVT's Valuation (43) in the null industry is somewhat better than the same rating for CYTK (100) in the Biotechnology industry. This means that IMVT’s stock grew somewhat faster than CYTK’s over the last 12 months.

CYTK's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for IMVT (100) in the null industry. This means that CYTK’s stock grew somewhat faster than IMVT’s over the last 12 months.

IMVT's SMR Rating (96) in the null industry is in the same range as CYTK (100) in the Biotechnology industry. This means that IMVT’s stock grew similarly to CYTK’s over the last 12 months.

CYTK's Price Growth Rating (38) in the Biotechnology industry is in the same range as IMVT (43) in the null industry. This means that CYTK’s stock grew similarly to IMVT’s over the last 12 months.

CYTK's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for IMVT (100) in the null industry. This means that CYTK’s stock grew significantly faster than IMVT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTKIMVT
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
86%
Momentum
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
80%
MACD
ODDS (%)
Bearish Trend 1 day ago
79%
Bearish Trend 1 day ago
77%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 8 days ago
79%
Bullish Trend 9 days ago
75%
Declines
ODDS (%)
Bearish Trend 1 day ago
78%
Bearish Trend 1 day ago
83%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CYTK
Daily Signal:
Gain/Loss:
IMVT
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVIFX21.500.16
+0.75%
Nomura International Core Equity C
RGAGX89.290.38
+0.43%
American Funds Growth Fund of Amer R6
BAGAX14.00N/A
N/A
Brown Advisory Growth Equity Adv
OTPSX40.49N/A
N/A
ProFunds NASDAQ-100 Svc
SUWZX39.50N/A
N/A
DWS Core Equity R6

IMVT and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with IDYA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMVT
1D Price
Change %
IMVT100%
-3.21%
IDYA - IMVT
53%
Loosely correlated
-1.81%
ROIV - IMVT
53%
Loosely correlated
-0.59%
CLDX - IMVT
48%
Loosely correlated
+2.89%
NRIX - IMVT
47%
Loosely correlated
-3.31%
NUVL - IMVT
47%
Loosely correlated
-1.37%
More